Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Alector, Inc. (ALEC) Stock Down -8.17% Today?

Why Is Alector, Inc. (ALEC) Stock Down -8.17% Today?

Key Takeaways

  • ALEC fell 8.17%, or $0.21, to $2.36 in Thursday's session, putting it among the weakest performers in small-cap biotechnology.
  • No company press release, SEC filing, analyst action, or clinical update accompanied the decline.
  • The move is a giveback from a roughly 45% rally between Oct. 2 and the Nov. 11 intraday 52-week high of $2.84, not a fresh fundamental shock.
  • The selling diverged from a firm sector tape: the SPDR S&P Biotech ETF (XBI) rose 0.63% and the iShares Biotechnology ETF (IBB) added 0.31%.
  • News Significance Score: 13/100 - no verified catalyst and a move only about 1.8 times the stock's typical daily swing.
  • Traders are watching whether $2.27, the 20-day moving average, holds, and any update on the AL137 first-in-human timeline.
  • Investors can review detailed Price Targets, Earnings history, and Forecast data on the dedicated pages.
  • Explore the Trending AI Robots page to see which automated strategies currently rank highest.

Opening Summary

Alector, Inc. (ALEC) is a South San Francisco clinical-stage biotechnology company developing antibody, enzyme, and siRNA therapies for neurodegenerative disease, built around its proprietary Alector Brain Carrier platform for shuttling drugs across the blood-brain barrier. Shares changed hands at $2.36 at midday Thursday, down $0.21, or 8.17%, from the prior close of $2.57. The direction is unambiguously negative. No verified news catalyst was found for the drop; the decline fits a pattern of profit-taking after a sharp six-week advance and a rejection at the stock's 52-week high.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found explains Thursday's decline. Alector has not published a press release, filed an 8-K, or disclosed trial or regulatory news this week, and no analyst rating or target change was issued ahead of the move. The most recent company-specific items were its third-quarter report on Nov. 5 and a $7 price objective from Wells Fargo on Nov. 13, both of which preceded the rally that peaked two sessions later.

The likely cause is technical and positioning-driven. Alector climbed from $1.81 on Oct. 2 to an intraday $2.84 on Nov. 11 — a 57% peak gain in 28 sessions — then failed to hold that level and began drifting lower. Thursday's action accelerated that retracement, with the stock breaking below its 10-day moving average near $2.47 but remaining above its 20-day average around $2.27. Short interest of roughly 8.4 million shares, about 3.6 days of trading volume, likely amplified the slide as momentum buyers exited. Thin liquidity in a sub-$400 million market capitalization name can turn a modest wave of sell orders into an outsized percentage move, and this is consistent with a routine retracement rather than a reassessment of the business.

Sector and Macro Backdrop

The broader environment was supportive, which makes Alector's decline idiosyncratic. Biotech benchmarks were higher, with XBI and IBB both in positive territory, and clinical-stage peers joined the advance: SRRK gained 4.79%, PRAX added 2.17%, and BEAM rose 1.86%. With the sector in the green, Alector's underperformance reflects stock-specific supply rather than a risk-off rotation. Attention in the space remains fixed on two FDA decisions scheduled for Nov. 22 involving Capricor and Savara, plus Alzheimer's data presentations this week — events that carry read-through for sentiment toward neurodegeneration names but not for Alector's own pipeline.

Market Context and Trading Activity

Turnover is running near a normal pace rather than showing the surge that typically accompanies news-driven selling, with roughly half a million shares changing hands by midday against a recent daily average of about 1.1 million. That profile supports a supply-and-demand explanation rather than an information shock. The stock traded as low as roughly $2.31, about 10% below the prior close, before stabilizing. It remains far above its 52-week low of $1.09 but has surrendered a meaningful slice of its autumn gains. The failure at $2.84 — the top of the range — and the loss of the 10-day average are the two technical markers that mattered most.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Alector's score is 13 out of 100.

The verified news component is essentially absent, contributing almost nothing, since nothing material was disclosed and the most recent corporate events were already public before the rally began. The price component is also low: an 8.17% decline is only about 1.8 times the stock's typical absolute daily move of roughly 4.5%, and moves of this size or larger occurred 11 times in the past 88 sessions. With both components weak, the combination produces a low score.

What Comes Next for ALEC

Alector's next scheduled financial update is its fourth-quarter and full-year report, expected in the first quarter of 2027. The company ended the third quarter with a cash runway projected into the second half of 2029, supported by the $100 million upfront payment from Genentech for AL050 and roughly $75 million in net proceeds from an October equity offering — a cushion that removes near-term financing pressure but also reflects dilution.

The pipeline calendar is thin. First-in-human subcutaneous dosing of AL137 in Australia is targeted for April 2027, with a U.S. IND submission planned for the second quarter of 2027, while AL164 and AL062 are not expected to enter the clinic until 2028. With no active clinical trials generating readouts, the shares are likely to remain driven by sentiment, analyst revisions, and sector rotation. Key risks include the absence of near-term catalysts, execution risk on early-stage programs, and the possibility that consensus expectations drift lower during the quiet period. Analyst opinion remains split, with ratings spanning Buy to Underweight.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots that cover thousands of tickers across equities, ETFs, and other markets, but only the strongest performers under current market conditions are surfaced in the curated Trending AI Robots section. Bots differ widely in strategy, timeframe, performance metrics, and the symbols they trade, so the selection refreshes as market conditions shift. Reviewing this list can help investors see which automated approaches are currently keeping pace with volatile names like Alector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALEC

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


ALEC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ALEC turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 64 cases where ALEC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.592). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders

Industry Biotechnology

Industry
Biotechnology
Address
131 Oyster Point Boulevard
Phone
+1 415 231-5660
Employees
103
Web
https://www.alector.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.